Travatan Z is owned by Novartis.
Travatan Z contains Travoprost.
Travatan Z has a total of 3 drug patents out of which 0 drug patents have expired.
Travatan Z was authorised for market use on 21 September, 2006.
Travatan Z is available in solution/drops;ophthalmic dosage forms.
The generics of Travatan Z are possible to be released after 13 October, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(4 years from now) | |
US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
9
United States
4
Japan
2
South Africa
2
Mexico
2
Australia
2
Hong Kong
2
Brazil
2
Spain
2
Korea, Republic of
2
Poland
2
China
2
Canada
2
European Union
1
Denmark
1
Austria
1
Russia
1
Slovenia
1
Uruguay
1
Argentina
1
Portugal
1
Cyprus
1
Chile
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic